Related Experiment Video

Updated: Aug 15, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Strategies for the treatment of imatinib-resistant chronic myeloid leukemia

Chi-hung Hui1, Timothy P Hughes

  • 1Hematology Division, Hanson Institute, Institute of Medical and Veterinary Science, Frome Road, Adelaide SA 5000, Australia. chi-hung.hui@imvs.sa.gov.au

Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
PubMed

Insights

Imatinib treatment alone may not cure chronic myeloid leukemia (CML). Strategies to overcome imatinib resistance and alternative therapies are crucial for CML patients, alongside new treatment approaches.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Imatinib is a primary treatment for chronic myeloid leukemia (CML).
  • Curative treatment for CML using imatinib alone remains a significant challenge.
  • Emergence of imatinib resistance and loss of responsiveness are critical clinical issues.

Purpose of the Study:

  • To review strategies for overcoming imatinib resistance in CML.
  • To discuss mechanisms underlying imatinib resistance.
  • To outline laboratory tests for assessing resistance and current clinical trials.

Main Methods:

  • Literature review of imatinib action and resistance mechanisms.
  • Description of diagnostic laboratory tests for imatinib resistance.
  • Overview of a contemporary Australian CML study.

Main Results:

  • Imatinib resistance is a major hurdle in CML treatment.
  • Understanding resistance mechanisms informs therapeutic strategies.
  • New approaches include dose intensification and combination therapies.

Conclusions:

  • Overcoming imatinib resistance is key to improving CML outcomes.
  • Alternative treatment strategies and combination therapies are essential.
  • Ongoing research and clinical trials are vital for advancing CML management.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...